Navigation Links
NYU Cancer Institute experts present at American Society of Clinical Oncology annual meeting
Date:5/21/2010

ress after initial therapy. Recent research shows this VEGF inhibitor may encourage greater invasiveness in patients with newly diagnosed and recurrent HGGs. In the study, researchers assessed tumor recurrence patterns in HGGs and their relation to survival in newly-diagnosed patients treated with bevacizumab. A retrospective analysis was completed for patients with newly diagnosed HGGs initially treated with surgery, radiation therapy, and the drug- temozolomide. Patients were given bevacizumab at 10 mg/kg once every two weeks until disease progression or toxicity. Research shows bevacizumab improve progression free and overall survival in patients. However, researchers concluded there is a marked increase in the number of diffuse recurrences over local recurrences following the additional bevacizumab therapy treatment. This shift in the pattern to diffuse recurrence is worrisome to researchers. Future clinical trials are needed to investigate strategies to block this more invasive progression.


Abstract # 8571: Sunday, June 6 at 12:00 PM in Chicago, IL
Hair Depigmentation as an Indicator of Durable Response to CTLA-4 Therapy
Presenter: Anna C. Pavlick, MS, MD Associate Professor of Medicine and Ronald O. Perelman Department of Dermatology, Director, NYU Melanoma Program, NYU Cancer Institute

Treatment with Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) monoclonal antibodies for metastatic melanoma has been known to induce immunologically related adverse events like skin eruptions and itching in some patients. However, it was unclear if these events are linked with clinical responses. Researchers report, for the first time, the occurrence of hair depigmentation following therapy with CTLA-4 monoclonal antibodies correlates with durable clinical responses. No non-responders to the treatment developed any hair depigmentation. This is the first documentation of hair depigmentation following treatment with CTLA-4 monoclonal antibod
'/>"/>

Contact: Lauren Woods
lauren.woods@nyumc.org
212-404-3753
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. Gene fusions may be the smoking gun in prostate cancer development, U-M study finds
2. Study raises new concerns about radiation and breast cancer
3. Slight changes in 2 key genes appear to launch breast cancer development
4. TGen researcher awarded American Cancer Society fellowship
5. Einstein researcher awarded prestigious cancer research grant
6. Cancer: Trapping the escape artist
7. U-M study achieves reduced side effects in head and neck cancer treatment
8. Milk and risk of renal cell cancer: Genetic research sheds new light
9. Multistage nanovector system provides sustained delivery of siRNA cancer therapeutic in mice
10. Key mechanism identified in metastatic breast cancer
11. Flaxseed-fed chickens shed light on ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... Bethesda, MDA combination of two techniques promises to ... while also reducing potential side effects says a new ... the FASEB Journal ( http://www.fasebj.org ). The ... involving the use of site-specific recombinases, or enzymes that ...
... and climatic zones move polewards, species will need to find ... the journal Molecular Ecology , has revealed that climate ... a range of new habitats. The study, led ... to understand the role of evolution in helping a species ...
... looks like bone. It feels like bone. For the most ... inkjet printer., Washington State University researchers have used a 3D ... be used in orthopedic procedures, dental work, and to deliver ... as a scaffold for new bone to grow on and ...
Cached Biology News:The newest of the new in gene therapy: 'Tag and target and exchange' 2British butterfly is evolving to respond to climate change 2
(Date:5/1/2015)... 2015 According to a ... (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by Technology ... Institutes) - Analysis & Global Forecast to 2019", ... Antibody Production Market for the forecast period of ... reach $2.572 Billion by 2019 from $1.425 Billion ...
(Date:4/30/2015)... Blythewood, South Carolina (PRWEB) May 01, 2015 ... steam system services, is extremely proud to announce that ... have been named as a winner of a Queen’s ... business success for the design and manufacture of a ... is the revolutionary alternative to traditional steam flow ...
(Date:4/30/2015)... 2015   Tamir Biotechnology , a leading developer ... its Ebola antiviral therapy program. Clinical ... currently being evaluated and considered by a number of ... During the first quarter of 2015, the company participated ... The Evaluation of Potential Treatments and Vaccines For Ebola ...
(Date:4/30/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... it has commenced an underwritten public offering of its ... underwriters a 30-day option to purchase up to an ... offered in the public offering. The offering is subject ... as to whether or when the offering may be ...
Breaking Biology Technology:Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... PETERSBURG, Va., Jan. 6 Star Scientific (Nasdaq ... Pharmaceuticals, Inc., in conjunction with its Star Tobacco, ... the ability of Stonewall(R) dissolvable smokeless tobacco ... an over-the-counter nicotine replacement product (NRT). The study, ...
... Inc., a leading provider,of software and high quality ... analysis , today announced that Bayer Schering Pharma ... years. Bayer Schering Pharma,has programs for cancer, ... coverage of these diseases and others. GeneGo ...
... Way For Use of ALD Ultra High-k Insulators; Marks ... ST. LOUIS, Jan. 6 ASM International N.V. (Nasdaq: ... and SAFC Hitech(TM), a business segment within SAFC(R), a ... ), today announced that they have entered into a ...
Cached Biology Technology:Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 2Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 3Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 4GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years 2ASM International N.V. and SAFC Hitech(TM) Sign Certified Manufacturer and Partnership Agreement 2ASM International N.V. and SAFC Hitech(TM) Sign Certified Manufacturer and Partnership Agreement 3ASM International N.V. and SAFC Hitech(TM) Sign Certified Manufacturer and Partnership Agreement 4
... Clean and Accurate Results Laser Capture ... the sensitivity and accuracy of molecular assays ... types and multi-cellular structures isolated from whole ... to microdissection-developed in 1996 at the National ...
Mouse monoclonal antibody raised against a partial recombinant DHX8. NCBI Entrez Gene ID = DHX8...
... raised against a partial recombinant ... K6HF (NP_004684, 141 a.a. ... protein with GST tag. ... NM_004693 Protein ...
... DNA Visualizer DX's sensitivity of DNA detection ... DNA band in an agarose gel can be ... this kit can be purified by organic solvent ... tested commercially kits worked well.) DNA excised ...
Biology Products: